Investigation into Option Care Health Sparks Concern Among Shareholders Over Securities Misrepresentation

Investigation of Option Care Health's Securities Practices

Overview

Recent developments concerning Option Care Health (NASDAQ: OPCH) have prompted Levi & Korsinsky to examine potential securities fraud linked to the company's misleading revenue guidance. On February 24, 2026, the CFO, Meenal Sethna, announced their confidence in maintaining a revenue expectation of between $5.8 billion and $6.0 billion for the fiscal year 2026. However, just a short 65 days later, a shocking announcement revised this guidance downward by as much as $225 million, bringing the new expectations to between $5.675 billion and $5.775 billion.

Background of the Situation

Investors who held shares of Option Care Health saw almost 30% of their investment evaporate following the release of the company’s Q1 2026 financial results. The announcement fell significantly short of analyst expectations, triggering a sell-off that resulted in a 26.4% drop in stock value shortly after the revenue guidance downgrade on April 30, 2026.

Management had included information regarding financial challenges during their earlier earnings call in February, highlighting a projected loss of $25 million to $35 million attributable to the Stelara biosimilar. However, the April revision tracked a staggering 600 basis point decline in expected revenue growth, mainly due to retention issues associated with CID patients and a shift in therapy types.

Investigation Focus

Levi & Korsinsky will evaluate whether the company adequately represented its financial position and potential risks when the February guidance was established. The law firm has cultivated a reputation as a leader in shareholder rights litigation and has reportedly recovered hundreds of millions of dollars for affected investors in past cases.

This investigation places considerable focus on understanding if misleading or false statements about FY 2026 revenue forecasts were made knowingly or with reckless disregard for accuracy. The consequences of such misinformation could pave the way for various legal implications as unhappy investors pursue remedies for their losses.

Investor Guidance

Affected investors are encouraged to compile essential brokerage documentation, including purchase dates, quantities of shares acquired, and the prices at which those shares were purchased. Levi & Korsinsky offers a free evaluation for affected parties to assess their eligibility to participate in the legal dialogue surrounding the security’s downturn.

FAQs Regarding the Investigation

- Q: Who is conducting the investigation?

A: The inquiry is led by Levi & Korsinsky, LLP, a firm recognized for its history of handling securities law violations.

- Q: Which statements are under scrutiny?

A: The focus is on statements concerning Option Care Health’s FY 2026 revenue guidance made on February 24 and subsequently retracted on April 30.

- Q: What is the impact on OPCH stock?

A: The company's stock price dropped by approximately 26.4% following the revenue miss and updated guidance.

- Q: What do affected investors need to do?

A: They should gather their transaction records and reach out to Levi & Korsinsky for a preliminary consultation at no upfront cost.

Conclusion

As Option Care Health navigates this tumultuous period, the ongoing investigation will shine a light on the validity of its past operations and financial disclosures. Shareholders who feel they were misled are urged to step forward and explore their potential claims. For those who have experienced significant losses, now is the time to seek the counsel of legal professionals who will work tirelessly to protect investor rights and bring accountability to potentially negligent corporate practices.